Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B round grosses $38mm for Civitas Therapeutics

Executive Summary

In its Series B round, Civitas Therapeutics Inc. (developing the ARCUS pulmonary drug delivery system for neurological, respiratory, and infectious diseases) raised $38 million from lead backer Bay City Capital, RA Capital, an undisclosed blue chip public investment firm, and all returning shareholders including Alkermes PLC (from which Civitas spun off in late 2010), Canaan Partners, Fountain Healthcare Partners, and Longitude Capital. Partners from Bay City and RA Capital joined the company’s board. The start-up will use the money to complete Phase IIb and start Phase III trials on its lead compound CVT301, a levodopa aerosol that acts as an adjunct therapy to oral levodopa for motor fluctuations (off episodes) in Parkinson’s disease.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies